CIViC Evidence Items

176 evidence items indexed

Evidence Level Distribution

CIViC evidence levels reflect study design quality, from A (strongest) to E (weakest).

AValidated — meta-analysis, systematic review, or major guideline

BClinical — prospective trial or retrospective cohort study

CCase study — single case report or small case series

DPreclinical — in vitro or animal model data

EInferential — computational prediction or biological rationale

Gene × Evidence Type

Count of CIViC evidence items per gene and evidence type category. Hover a column header for the type definition.

	Predictive	Diagnostic	Prognostic	Functional	Predispos.	Oncogenic
BCR::ABL1	323	11
BRAF	186	4	26	2		1
EGFR	248		12	3		2
EML4::ALK	64
ERBB2	142		2
FLT3	55	2	21
KIT	102	3	7
KRAS	159	4	24			4
PIK3CA	156		16	4
PTEN	53	1	3	1	2	1
TP53	52		40	100	2
VHL	5	2	3		635	15

Predictive:Links a variant to treatment response or resistance

Diagnostic:Supports or refutes a specific disease diagnosis

Prognostic:Informs disease progression or clinical outcome

Functional:Characterises the biological effect of a variant

Predisposing:Germline variant associated with cancer predisposition

Oncogenic:Characterises the variant's role in oncogenesis

Level	Gene	Variant	Type	Direction	Significance	Disease	Drugs	Source
A	PIK3CA	Mutation	Predictive	Supports	Sensitivity/Response	Breast Cancer	Alpelisib,Fulvestrant	André et al., 2019
A	PIK3CA	Q546E OR PIK3CA Q546R	Predictive	Supports	Sensitivity/Response	Breast Cancer	Alpelisib,Fulvestrant	André et al., 2019
A	PIK3CA	H1047R OR PIK3CA H1047Y OR PIK3CA H1047L	Predictive	Supports	Sensitivity/Response	Breast Cancer	Fulvestrant,Alpelisib	André et al., 2019
D	PIK3CA	E542K	Predictive	Supports	Sensitivity/Response	Breast Cancer	Izorlisib	Tanaka et al., 2011
D	PIK3CA	H1047R	Predictive	Supports	Sensitivity/Response	Breast Cancer	Izorlisib	Tanaka et al., 2011
B	PIK3CA	Mutation	Predictive	Supports	Resistance	Colorectal Cancer	Anti-EGFR Monoclonal Antibody	Wu et al., 2013
B	PIK3CA	Mutation	Predictive	Supports	Sensitivity/Response	Her2-receptor Positive Breast Cancer	Everolimus	André et al., 2016
D	PIK3CA	Mutation	Predictive	Supports	Sensitivity/Response	Cancer	Alpelisib	Fritsch et al., 2014
D	PIK3CA	Mutation	Predictive	Supports	Sensitivity/Response	Breast Cancer	Ribociclib,Phosphatidylinositide 3-Kinase Inhibitor	Vora et al., 2014
D	PIK3CA	E545K	Predictive	Supports	Sensitivity/Response	Her2-receptor Positive Breast Cancer	Pictilisib	O'Brien et al., 2010
D	PIK3CA	K111N	Predictive	Supports	Sensitivity/Response	Her2-receptor Positive Breast Cancer	Pictilisib	O'Brien et al., 2010
D	PIK3CA	H1047R	Predictive	Supports	Sensitivity/Response	Her2-receptor Positive Breast Cancer	Pictilisib	O'Brien et al., 2010
B	PIK3CA	Mutation	Predictive	Supports	Sensitivity/Response	Cancer	Capivasertib	Hyman et al., 2017
B	PIK3CA	Exon 21 Mutation	Prognostic	Supports	Better Outcome	Breast Cancer		Barbareschi et al., 2007
B	PIK3CA	Exon 10 Mutation	Prognostic	Supports	Poor Outcome	Breast Cancer		Barbareschi et al., 2007
D	PIK3CA	H1047R	Predictive	Supports	Resistance	Her2-receptor Positive Breast Cancer	Lapatinib,Trastuzumab	Eichhorn et al., 2008
D	PIK3CA	H1047R	Predictive	Does Not Support	Resistance	Her2-receptor Positive Breast Cancer	Dactolisib	Eichhorn et al., 2008
A	PIK3CA	E545K OR PIK3CA E545A OR PIK3CA E545G OR PIK3CA E545D	Predictive	Supports	Sensitivity/Response	Breast Cancer	Alpelisib,Fulvestrant	André et al., 2019
C	PIK3CA	V955I	Predictive	Supports	Resistance	Colorectal Cancer	Cetuximab	Xu et al., 2017
C	PIK3CA	K944N	Predictive	Supports	Resistance	Colorectal Cancer	Cetuximab	Xu et al., 2017
C	PIK3CA	F930S	Predictive	Supports	Resistance	Colorectal Cancer	Cetuximab	Xu et al., 2017
C	PIK3CA	V955G	Predictive	Supports	Resistance	Colorectal Cancer	Cetuximab	Xu et al., 2017
C	PIK3CA	K966E	Predictive	Supports	Resistance	Colorectal Cancer	Cetuximab	Xu et al., 2017
A	PIK3CA	C420R	Predictive	Supports	Sensitivity/Response	Breast Cancer	Fulvestrant,Alpelisib	André et al., 2019
B	PIK3CA	Mutation OR PTEN Mutation OR PIK3R1 Mutation	Predictive	Supports	Sensitivity/Response	Colorectal Cancer	Aspirin	Martling et al., 2025
B	PIK3CA	E542K	Predictive	Does Not Support	Resistance	Colorectal Cancer	Regorafenib Anhydrous	Tabernero et al., 2015
B	PIK3CA	Exon 10 Mutation	Predictive	Does Not Support	Resistance	Colorectal Cancer	Cetuximab,Chemotherapy	De Roock et al., 2010
B	PIK3CA	Exon 21 Mutation	Predictive	Supports	Resistance	Colorectal Cancer	Chemotherapy,Cetuximab	De Roock et al., 2010
D	PIK3CA	E542K	Predictive	Supports	Sensitivity/Response	Breast Cancer	Sirolimus	Kang et al., 2005
C	PIK3CA	E545K	Predictive	Supports	Resistance	Colorectal Cancer	Panitumumab,Cetuximab	Sartore-Bianchi et al., 2009
B	PIK3CA	Amplification	Prognostic	Supports	Poor Outcome	Gastric Adenocarcinoma		Shi et al., 2012
D	PIK3CA	E545K	Predictive	Supports	Sensitivity/Response	Breast Cancer	Akt Inhibitor MK2206,Pictilisib	Beaver et al., 2013
C	PIK3CA	P471L	Predictive	Supports	Sensitivity/Response	Merkel Cell Carcinoma	Idelalisib	Shiver et al., 2015
D	PIK3CA	Mutation	Predictive	Supports	Sensitivity/Response	Colorectal Cancer	Cabozantinib	Song et al., 2015
B	PIK3CA	Mutation	Predictive	Does Not Support	Sensitivity/Response	Endometrial Cancer	Ridaforolimus,Temsirolimus	Mackay et al., 2014
D	PIK3CA	Mutation	Predictive	Supports	Sensitivity/Response	Head And Neck Cancer	Dactolisib	Lui et al., 2013
D	PIK3CA	Amplification	Predictive	Supports	Sensitivity/Response	Stomach Carcinoma	Alpelisib	Fritsch et al., 2014
D	PIK3CA	H1047R	Predictive	Supports	Sensitivity/Response	Lung Adenocarcinoma	Dactolisib	Engelman et al., 2008
D	PIK3CA	Mutation	Predictive	Supports	Sensitivity/Response	Head And Neck Squamous Cell Carcinoma	Radiation Therapy,Taselisib	Zumsteg et al., 2016
D	PIK3CA	Mutation	Predictive	Supports	Sensitivity/Response	Stomach Cancer	Capivasertib	Li et al., 2013
D	PIK3CA	Mutation	Predictive	Supports	Sensitivity/Response	Cancer	Capivasertib	Davies et al., 2012
D	PIK3CA	H1047R	Predictive	Supports	Sensitivity/Response	Her2-receptor Positive Breast Cancer	Trastuzumab,Capivasertib	Davies et al., 2012
D	PIK3CA	H1047R	Predictive	Supports	Sensitivity/Response	Her2-receptor Positive Breast Cancer	Capivasertib,Lapatinib	Davies et al., 2012
D	PIK3CA	Mutation	Predictive	Supports	Sensitivity/Response	Breast Cancer	Palbociclib,Phosphatidylinositide 3-Kinase Inhibitor	Vora et al., 2014
D	PIK3CA	Mutation	Predictive	Supports	Sensitivity/Response	Breast Cancer	Everolimus,MTOR Kinase Inhibitor PP242	Weigelt et al., 2011
D	PIK3CA	Mutation	Predictive	Supports	Sensitivity/Response	Endometrial Cancer	Pictilisib	Weigelt et al., 2013
D	PIK3CA	H1047R	Predictive	Supports	Sensitivity/Response	Thyroid Cancer	Perifosine,Temsirolimus	Liu et al., 2009
D	PIK3CA	E542K	Predictive	Supports	Sensitivity/Response	Thyroid Cancer	Perifosine,Temsirolimus	Liu et al., 2009
C	PIK3CA	C420R	Predictive	Does Not Support	Resistance	Colorectal Cancer	Cetuximab	De Roock et al., 2010
B	PIK3CA	Mutation	Prognostic	Supports	Better Outcome	Breast Cancer		Kalinsky et al., 2009

Page 1 of 4